BRL Medicine Inc.

Cell Journal Release! BRL Medicine's world's first allogeneic universal CAR-T therapy

It's been more than 4 years since the first patient with β-thalassemia was cured with BRL Medicine's gene therapy

BRL Medicine's new generation universal CAR-T therapy has been approved for IND in China

BRL Medicine's world's first non viral PD1 targeted integration CAR-T product BRL-201 has been approved for IND in China

MORE

BRL Medicine's first CRISPR/Cas9 gene therapy "BRL-101" has been approved for IND in China

MORE

About BRL Medicine

At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 19 Investigator-Initiated clinical Trials (IIT) in 20 leading hospitals in China, with many pipeline projects have entered into IND application stage.

Learn More